NVO Company Profile and Key Details

NYSE : NVO

Novo Nordisk A/S

$47.64

4.3+9.92%

At Close 4:00 PM

58.48

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Novo Nordisk A/S (NVO) stock surged +9.92%, trading at $47.64 on NYSE, up from the previous close of $43.34. The stock opened at $46.37, fluctuating between $45.84 and $47.73 in the recent session.

Stock Snapshot

43.34

Prev. Close

211.71B

Market Cap

45.84

Day Low

13.09

P/E Ratio

3.64

EPS (TTM)

15.68

Cash Flow per Share

46.37

Open

4.44B

Number of Shares

47.725

Day High

100%

Free Float in %

23.87

Book Value

34.47M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 06, 2026	46.37	47.74	45.84	47.64	35.73M
Feb 05, 2026	45.05	45.67	43.24	43.34	53.4M
Feb 04, 2026	47.95	49.10	46.47	47.19	46.49M
Feb 03, 2026	58.35	58.64	49.96	50.30	69.23M
Feb 02, 2026	57.91	59.30	57.79	58.93	16.6M
Jan 30, 2026	59.27	59.91	58.59	59.43	12.03M
Jan 29, 2026	59.93	59.93	58.80	59.33	15.74M
Jan 28, 2026	61.48	61.56	59.99	60.33	16.08M
Jan 27, 2026	62.89	63.49	62.49	62.89	13.35M
Jan 26, 2026	62.88	64.00	62.68	63.98	19.92M
Jan 23, 2026	63.40	64.16	62.03	62.26	27.79M
Jan 22, 2026	61.44	62.44	61.04	62.23	20.16M
Jan 21, 2026	60.01	60.17	57.56	59.32	30.12M
Jan 20, 2026	60.22	62.18	59.96	60.68	30.28M
Jan 16, 2026	59.91	62.40	59.24	62.33	42.74M
Jan 15, 2026	57.79	57.84	56.29	57.12	25.66M
Jan 14, 2026	58.84	59.75	58.34	58.91	16.11M
Jan 13, 2026	60.58	60.63	59.14	59.64	16.78M
Jan 12, 2026	60.14	60.30	59.10	59.86	18.99M
Jan 09, 2026	59.47	60.64	58.78	58.81	28.89M

Contact Details

Bagsvaerd, 2880

Denmark

https://www.novonordisk.com 454 444 8888

About Company

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Peers

LLY

37.34+3.66%

Eli Lilly and Company$1,058.18 JNJ

2.2+0.93%

Johnson & Johnson$239.99 ABBV

4.41+2.01%

AbbVie Inc.$223.43 NVS

2.47+1.60%

Novartis AG$156.42 MRK

2.18+1.82%

Merck & Co., Inc.$121.93 BMY

2.47+4.15%

Bristol-Myers Squibb Company$61.99 GSK

1.06+1.79%

GSK plc$60.23 PFE

0.73+2.76%

Pfizer Inc.$27.22 OGN

0.11+1.36%

Organon & Co.$8.21 SRXH

-0.0029-2.25%

SRx Health Solutions Inc.$0.13

Company Overview

Novo Nordisk A/S (NYSE:NVO) closed at $47.64 USD, gaining $4.30 (9.92%) from the previous close of $43.34. The stock is currently mid-range between its 52-week high and low $43.08 and $93.80. With a market capitalization of about $211.71 billion, Novo Nordisk A/S is classified as a mega-cap and shows lower-than-market volatility (beta ~0.40). Key stats such as the average daily volume over the past year has been around 21.67 million shares, trading with heavier-than-usual volume. Headquartered in Bagsvaerd, None, Novo Nordisk A/S operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Maziar Mike Doustdar, the company employs approximately 77,406 people and listed since April 30, 1981. Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -17.47%, SMA50 -10.46%, SMA200 -18.68%). The stock’s 14-day RSI is 37.0 (weak momentum), while the ATR of 2.84 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -49.21% below its high and over 10.58% above its low. Average 10-day trading volume of 30.96 million shares is slightly above the 3-month average of 21.88 million, indicating heightened recent market interest.

Valuation Metrics

Novo Nordisk A/S trades at a P/E ratio of 13.01, slightly below the S&P 500 average, with a price-to-sales ratio of 4.31 and a price-to-book ratio of 6.87 trading at moderately above to book value. The P/FCF stands at 23.7, also above market averages.

Dividend & Fair Value

Novo Nordisk A/S last paid a dividend of 1.23 per share, this equals a trailing yield of roughly 7.22%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $237.41. This means the shares are trading below this model’s fair value.

Shareholding & Insider Activity

Novo Nordisk A/S has 3.37 billion shares outstanding. The public float is 3.19 billion shares, elevated short interest at 0.62% of float. This equals 21.02 million shares. The short ratio is 0.89 days. Institutional investors hold 9.36% of the float. Insiders own 0.01%.

Financial & Profitability Overview

Over the trailing twelve months, Novo Nordisk A/S generated $232.26B in revenue, or $51.67 per share. Gross margin was 84.60%, operating margin 44.16%, and net profit margin 36.03%. Returns are exceptional, with ROA at 26.61% and ROE at 78.53%.
On valuation metrics, Novo Nordisk A/S trades at a P/E of 13.01, P/S of 4.31 and P/B of 6.87. Liquidity is tight, with a current ratio of 0.80 and quick ratio of 0.57. Operationally, the company’s inventory turnover is 1.14 and cash conversion cycle is 282.23 days. Debt-to-equity is 0.67, supported by a cash flow-to-debt ratio of 0.91.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Novo Nordisk A/S posted revenue of $232.26B, down slightly from $176.95B in the prior quarter. Gross profit was $196.50B (margin 84.60%). Operating income was $102.57B (margin 44.2%). Net income was$83.68B (EPS $18.67).
The company ended the quarter with $30.23B in cash and short-term investments, a total debt of $27.01B, and net debt of $12.61B. Total assets were $314.49B, with equity of $106.56B. Financials further reflected robust performance, with operating cash flow of $108.91B, free cash flow of $70.01B, and capital expenditures of - $38.90B.

Price Forecast & Outlook

Our AI price prediction model suggests that Novo Nordisk A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.54%, with price expected at $42.62 by February 19, 2026, within a range of $39.88 to $45.55 3-Month Outlook: Projected fall of -26.7%, reaching $34.92 by May 06, 2026, with a range of $32.60 to $37.03. 1-Year Outlook: Projected loss of -17.88%, with price at $39.12 by February 05, 2027, within a range of $30.88 to $51.05.

Key Takeaways

Novo Nordisk A/S (NYSE:NVO) shares are up 19.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Novo Nordisk A/S trading at a premium to the broader market with a P/E of 13.01. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $113.15, suggesting 137.51% upside. Our AI forecast model points to short-term weakness (-10.54% over two weeks), a medium-term fall (-26.7% over three months), and a longer-term loss (-17.88% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Novo Nordisk A/S (NVO) stock price?

Novo Nordisk A/S (NYSE: NVO) stock price is $47.64 in the last trading session. During the trading session, NVO stock reached the peak price of $47.73 while $45.84 was the lowest point it dropped to. The percentage change in NVO stock occurred in the recent session was 9.92% while the dollar amount for the price change in NVO stock was $4.30.

NVO's industry and sector of operation?

The NYSE listed NVO is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Novo Nordisk A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NVO?

No Data

How NVO did perform over past 52-week?

NVO's closing price is 10.59% higher than its 52-week low of $43.08 where as its distance from 52-week high of $93.80 is -49.21%.

How many employees does NVO have?

Number of NVO employees currently stands at 77,406.

Link for NVO official website?

Official Website of NVO is: https://www.novonordisk.com

How do I contact NVO?

NVO could be contacted at phone 454 444 8888 and can also be accessed through its website. NVO operates from Novo Alle 1, Bagsvaerd, 2880, Denmark.

How many shares of NVO are traded daily?

NVO stock volume for the day was 34.47M shares. The average number of NVO shares traded daily for last 3 months was 21.67M.

What is the market cap of NVO currently?

The market value of NVO currently stands at $211.71B with its latest stock price at $47.64 and 4.44B of its shares outstanding.

Employees	77406
Beta	0.36
Sales or Revenue	$232.26B
5Y Sales Change%	1.242%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

NVO Company Profile and Key Details

Novo Nordisk A/S

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook